Vistagen Therapeutics, Inc.
refisolone nasal spray
moderate to severe vasomotor symptoms (also known as “hot flashes”) due to menopause
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews refisolone nasal spray for moderate to severe vasomotor symptoms (also known as “hot flashes”) due to menopause around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“The FDA’s Study May Proceed letter enables the Company to pursue further Phase 2 clinical development of refisolone in the U.S., building on successful exploratory Phase 2a clinical studies for the treatment of menopausal hot flashes and pr”